関連する実験動画

Updated: May 3, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

CYP4A1120-hydroxyeicosatetraenoic acid synthaseの機能的変異は,本質的な高血圧と関連しています

James V Gainer¹, Aouatef Bellamine, Elliott P Dawson

¹Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical School, Nashville, Tenn 37232-0146, USA.

|December 22, 2004

まとめ

CYP4A11遺伝子 (T8590C) の遺伝的変異は,20-ヒドロキシイコサテトラエノ酸 (20-HETE) の生成を減少させます. この変種は,特定の集団における高血圧リスクの増加と関連しており,血圧調節におけるその役割を強調しています.

科学分野:

遺伝学遺伝学とは
バイオケミストリーバイオケミストリー
心血管医学心血管医学

背景:

CYP4A11は,腎臓機能における重要な代謝産物である20-ヒドロキシエコサテトラエノ酸 (20-HETE) を生成する酵素です.
CYP4A11の遺伝的変異は,その酵素活性に影響を与え,血圧の調節に影響を与える可能性があります.
マウスでの研究では,関連する遺伝子 (Cyp4a14) の障害が重度の高血圧を引き起こすことが示されています.

研究の目的:

ヒトのCYP4A1120-HETE合成酵素の機能的な変異を特定する.
ヒト集団における高血圧とこの変異体の関連性を調査する.

主な方法:

分子および生化学分析を使用して,CYP4A11変異体を特定し,特徴づけました.
ティミジンからサイトシン (T8590C) のポリモルフィズムが特定され,アミノ酸置換 (フェニララニンからセリンへの位置434) に繋がりました.
変異体の機能的影響は,アラキドン酸 (AA) とラウリック酸の代謝活性を測定することによって評価されました. 症例対照関連研究は,2つの独立したヒト集団 (テネシー州の白人およびフレミングハム心臓研究) で実施されました.

主要な成果:

T8590Cの変種は,AAとラウリック酸を代謝する活性が著しく低下したタンパク質を生成しました.
白人の集団では,8590Cの変種は高血圧の確率を2.31倍に増加させた.
フレミングハム心臓研究では,8590Cの変種は高血圧との関連に傾向を示し,特に糖尿病を除外したとき. 黒人集団では関連性が見つかりませんでした.

結論:

ヒトCYP4A11の機能的変種 (T8590C) が特定され,20-HETE合成酵素の活性が低下しました.
この変種は高血圧に関連しており,多遺伝子血圧制御におけるその役割を支持しています.
T8590C変異の臨床的関連性は,高血圧などの併発性疾患と人口統計に基づいて異なる可能性があります.

さらに関連する動画

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

関連する概念動画

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...